Verve Therapeutics Inc. was sued by a shareholder who accuses the biotech company of misleading investors about a clinical trial for its cholesterol medicine.
The proposed class action, filed Tuesday in the US District Court for the District of Massachusetts, said Boston-based Verve overstated the potential of a drug delivery system and emphasized successful interim data without warning its clinical trial could be stopped if there were an adverse event.
Verve in April paused enrollment in a clinical trial after a participant experienced an adverse reaction, including a low blood platelet count.
“Defendants’ statements about its business, operations, and prospects, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.